Takeda Pharmaceutical (TAK) Income from Continuing Operations (2017 - 2026)
Takeda Pharmaceutical (TAK) posted quarterly Income from Continuing Operations of 1331196637.58 for Q2 2026, up 8.83% year-over-year from 1223134448.09 in Q2 2025, and down 1.62% quarter-over-quarter from 1353103907.52 in Q1 2026.
Takeda Pharmaceutical (TAK) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Takeda Pharmaceutical's Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 1331196637.58 for Q2 2026.
- In Q2 2026, Income from Continuing Operations rose 8.83% year-over-year to 1331196637.58; the TTM figure through Jun 2026 stood at 1941500707.1 (down 49.6% YoY), while the FY2026 annual figure was 1010594468.53, down 242.35% from the prior year.
- Income from Continuing Operations for Q2 2026 stood at 1331196637.58, down from 1353103907.52 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2776463151.57 in Q3 2025, with the low at 3519262989.58 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 1288045864.58 (2025), against an average of 1022900313.55.
- The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations surged 297.92% in 2023, then sank 4440.99% in 2024.
- Takeda Pharmaceutical's Income from Continuing Operations stood at 673551561.9 in 2022, then plunged by 96.58% to 23001791.23 in 2023, then tumbled by 4440.99% to 998506189.95 in 2024, then plunged by 252.45% to 3519262989.58 in 2025, then soared by 137.83% to 1331196637.58 in 2026.
- Business Quant data shows TAK's Income from Continuing Operations at 1331196637.58 in Q2 2026, 1353103907.52 in Q1 2026, and 3519262989.58 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.80 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.05 Bn | 39.39 Bn | 2.15 Bn | -576.00 Mn |
| 3 | Zoetis | 31.51 Bn | 29.84 Bn | 1.05 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.70 Bn | 22.90 Bn | 5.10 Bn | 1.33 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 333.00 Mn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | -118.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 144.40 Mn |
| 8 | Elanco Animal Health | 12.06 Bn | 11.53 Bn | 798.00 Mn | 54.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Alkermes | 8.27 Bn | 7.61 Bn | 397.90 Mn | 524,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.33 Bn |
| Mar 31, 2026 | 1.35 Bn |
| Dec 31, 2025 | -3.52 Bn |
| Sep 30, 2025 | 2.78 Bn |
| Jun 30, 2025 | 1.22 Bn |
| Mar 31, 2025 | 1.26 Bn |
| Dec 31, 2024 | -998.51 Mn |
| Sep 30, 2024 | 2.37 Bn |
| Jun 30, 2024 | 1.14 Bn |
| Mar 31, 2024 | 1.23 Bn |
| Dec 31, 2023 | 23.00 Mn |
| Sep 30, 2023 | 1.94 Bn |
| Jun 30, 2023 | 1.32 Bn |
| Mar 31, 2023 | 1.56 Bn |
| Dec 31, 2022 | 673.55 Mn |
| Sep 30, 2022 | 487.77 Mn |
| Jun 30, 2022 | 1.59 Bn |
| Mar 31, 2022 | 2.65 Bn |
| Dec 31, 2021 | 761.54 Mn |
| Sep 30, 2021 | 698.55 Mn |